Summarized by Masters of Longevity from PR Newswire.
Blood cancer philanthropy news about an expanded venture-style therapy acceleration program and how donors can boost early-stage drug development.
Key Takeaways
- Royalty Pharma donated $7.5 million to Blood Cancer United's Therapy Acceleration Program.
- TAP-supported programs have yielded six FDA approvals or guideline inclusions and over 30 active clinical studies.
